التفاصيل البيبلوغرافية
| العنوان: |
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. |
| المؤلفون: |
Pavel, Marianne E.1, Hainsworth, John D.2, Baudin, Eric3, Peeters, Marc4, Dieter Hörsch5,6, Winkler, Robert E.7, Klimovsky, Judith7, Lebwohl, David7, Jehl, Valentine8, Wolin, Edward M.9, Öberg, Kjell10, Van Cutsem, Eric11, Yao, James C.12 jyao@mdanderson.org |
| المصدر: |
Lancet. 12/10/2011, Vol. 378 Issue 9808, p2005-2012. 8p. |
| مصطلحات موضوعية: |
*RANDOMIZED controlled trials, *PLACEBOS, *NEUROENDOCRINE tumors, *CARCINOID, *TUMOR treatment, *PATIENTS |
| مستخلص: |
The article presents a randomised, placebo-controlled study which compares placebo with everolimus, both in conjunction with octreotide LAR. Participants were people 18 years old and older having intermediate-grade or low-grade advanced neuroendocrine tumours. The study reveals that everolimus with octreotide LAR improved progression-free survival in advanced neuroendocrine tumour patients associated with carcinoid syndrome. |
| قاعدة البيانات: |
Academic Search Index |
